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LATE BREAKING ABSTRACTS
PLENARY ABSTRACTS
A PHASE III, MULTICENTER, PLACEBO-CON-
TROLLED, DOUBLE-BLIND, RANDOMIZED CLINICAL
TRIAL TO EVALUATE THE EFFICACY OF B EVACI-
ZUMAB (AVASTIN®) IN COMBINATION WITH ERLO-
TINIB (TARCEVA®) COMPARED WITH ERLOTINIB
ALONE FOR TREATMENT OF ADVANCED NON-SMALL
CELL LUNG CANCER AFTER FAILURE OF STANDARD
FIRST-LINE CHEMOTHERAPY (BETA)
J. Hainsworth1, R. Herbst2, 1Sarah Cannon Cancer Center, Nashville, TN;
2MD Anderson Cancer Center, Houston, TX
Background: Bevacizumab (B) with chemotherapy and erlotinib (E)
monotherapy have demonstrated a survival benefit in the treatment of
patients (pts) with advanced NSCLC (Sandler et al, NEJM 2006; Shepherd
et al, NEJM 2005). Randomized phase II data supported the hypothesis
that combining BE might improve efficacy, with acceptable safety.
(Herbst et al, JCO 2007).
Methods: Pts with advanced NSCLC who progressed during or after 1st line
therapy were enrolled. The primary endpoint of the trial was overall survival
(OS). Secondary endpoints included progression free survival (PFS) and
objective response rate (ORR). Eligible pts were B appropriate, including a
group with treated brain metastases, squamous cell disease at low risk for
bleeding, and those requiring anticoagulation. Previous anti-angiogenisis or
epidermal growth factor receptor (EGFR) targeted therapy was not allowed.
Pts were randomized (1:1) to BE or E placebo (P). E dosing was 150 mg
daily. B/P dosing was 15mg/kg intravenous every 3 weeks. Responses were
assessed every 6 weeks until week 24 and every 12 weeks thereafter.
Treatment continued until disease progression or unacceptable toxicity.
Results: 636 patients were enrolled from June 2005 to April 2008. The final
analysis was conducted after 418 deaths were recorded. Median
OS was 9.3 mos (BE) vs.9.2 mos (EP), p  0.75, HR0.97 (95% CI:
0.801.18). Median PFS was 3.4 mos (BE) vs. 1.7 mos (EP), p0.0001;
HR0.62 (95%CI: 0.52–0.75). ORR was 12.6% (BE) vs.6.2% (EP),
p0.006. The safety profile for BE was consistent with known profiles for
B and E and will be described further at presentation.
Conclusions: The addition of B to E in the BETA lung study was not
associated with an improvement in overall survival. However, BE
doubled PFS and ORR providing clear evidence of clinical activity.
Author Disclosures: J. Hainsworth, Genentech, Inc; R. Herbst, Genen-
tech, Inc; Genentech, Inc; Genentech, Inc.
GEFITINIB (G) VS CARBOPLATIN/PACLITAXEL (C/P)
IN CLINICALLY SELECTED CHEMONAı¨VE PATIENTS
(PTS) WITH ADVANCED NON-SMALL-CELL LUNG
CANCER (NSCLC) IN ASIA (IPASS): RANDOMIZED,
OPEN-LABEL, PHASE III STUDY
T. S. Mok1, S. Leong2, X. Liu3, Y. Ichinose4, V. Sriuranpong5, C. Liam6,
Y. Chen7, E. Duffield8, Y. Rukazenkov8, M. Fukuoka9, 1The Chinese
University of Hong Kong, Hong Kong, China; 2National Cancer Centre of
Singapore, Singapore, Singapore; 3Beijing Cancer Hospital, Beijing,
China; 4National Hospital Organization Kyushu Cancer Center, Fukuoka,
Japan; 5Chulalongkorn University, Bangkok, Thailand; 6University of
Malaya, Kuala Lumpar, Malaysia; 7Tapei Veterans General Hospital,
Taipei, Taiwan; 8AstraZeneca, Macclesfield, United Kingdom; 9Kinki
University, Osaka, Japan
Objective: The Phase III IRESSA™ Pan ASia Study (IPASS) compared
efficacy, safety and tolerability of G with C/P in clinically selected
chemonaı¨ve pts with advanced NSCLC.
Methods: From Mar 06 to Oct 07, chemonaı¨ve, never- or light ex-smokers
with WHO PS 0–2, adenocarcinoma histology and stage IIIB/IV NSCLC
were randomized to G 250 mg/day (n609) or C (AUC 5 or 6)/P (200
mg/m2) (n608). Primary objective was to assess noninferiority of G vs C/P
for PFS in ITT population; secondary endpoints were objective response rate
(ORR, RECIST), overall survival (OS), QoL (FACT-L, TOI), symptom
improvement (LCS subscale of FACT-L), and tolerability. Association of
efficacy with EGFR biomarkers was an exploratory objective.
Results: Primary objective was exceeded with G superior to C/P for PFS (HR
0.74; 95% CI 0.65–0.85; p.0001). PFS difference was not constant, favor-
ing C/P for first 6 mths and G for remaining 16 mths, potentially driven by
differences in PFS outcomes for pts with EGFRmutation (M) and - tumors.
PFS was longer for G than C/P (HR 0.48; 95% CI 0.36–0.64; p.0001) in
M pts and longer with C/P than G (HR 2.85; 95% CI 2.05–3.98; p.0001)
inM- pts. ORRwas significantly higher with G than C/P (43.0 vs 32.2%; odds
ratio OR 1.59; 95% CI 1.25–2.01; p.0001). OS was similar for G and C/P
(HR 0.91; 95% CI 0.76–1.10; median OS 18.6 vs 17.3 mths; 37% maturity);
follow-up is ongoing. QoL improvement rates (FACT-L, TOI) were higher
with G than C/P; symptom improvement rates (LCS) were similar. G had a
more favorable tolerability profile. OS for EGFR M and M- sub-
groups will be presented in meeting.
Conclusions: This study demonstrated superior efficacy in terms of PFS
and ORR, QoL improvement rates, similar OS and symptom improve-
ment rates and more favorable tolerability profile for G compared with
C/P in chemonaı¨ve, never- or light ex-smokers with advanced NSCLC
and adenocarcinoma histology. PFS initially favored C/P and then G,
likely driven by different outcomes according to EGFR mutation
status.
Author Disclosures: T.S. Mok, Astrazeneca; Roche; Pfizer; Eli Lilly; S.
Leong, Eli Lilly; X. Liu, None; Y. Ichinose, None; V. Sriuranpong,
None; C. Liam, None; Y. Chen, Astrazeneca; Eli Lilly; E. Duffield,
Astrazeneca; Y. Rukazenkov, Astrazeneca; M. Fukuoka, Astrazeneca;
Chugai; Takeda; Merck Serono.
FIRST-LINE BEVACIZUMAB COMBINED WITH CIS-
PLATIN/GEMCITABINE (CG) IN PATIENTS (PTS) WITH
ADVANCED OR RECURRENT NON-SQUAMOUS, NON-
SMALL CELL LUNG CANCER (NSCLC): AVAIL
(BO17704), A PHASE III RANDOMISED STUDY
M. Reck1, J. von Pawel2, P. Zatlouka3, R. Ramlau4, V. Gorbounova5, V.
Hirsh6, N. Leighl7, J. Mezger8, V. Archer9, C. Manegold10, 1Hospital
Grosshandorf, Grosshansdorf, Germany; 2Asklepios Fachkliniken
Muenchen-Gauting, Gauting, Germany; 33rd Faculty of Medicine,
Charles University, Prague, Czech Republic; 4Regional Center of Lung
Diseases, Poznan, Poland; 5Cancer Research Center, Moscow, Russian
Federation; 6McGill University Health Centre (MUHC), Montreal, QC,
Canada; 7Princess Margaret Hospital, Toronto, ON, Canada; 8St Vincen-
tius Kliniken Karlsruhe, Karlsruhe, Germany; 9F. Hoffmann-La Roche,
Ltd, Welwyn Garden City, United Kingdom; 10University Medical Center,
Mannheim, Germany
Background: Adding bevacizumab (Bev) to carboplatin/paclitaxel im-
proved overall (OS) and progression-free survival (PFS) in pts with
advanced NSCLC in the E4599 study Sandler et al. NEJM 2006. This
study (BO17704) evaluated the efficacy and safety of Bev plus CG in pts
with advanced NSCLC.
Methods: A double-blind trial that randomised 1,043 pts to C 80mg/m2 (d1)
and G 1,250mg/m2 (d1 and d8) q3w for up to 6 cycles plus either Bev
7.5mg/kg q3w (n345), Bev 15mg/kg q3w (n351) or placebo (n347).
Bev/placebo was administered until disease progression (PD). Key eligibility
criteria: histologically or cytologically documented chemo-naive locally ad-
vanced, metastatic or recurrent non-squamous NSCLC; ECOG PS 0/1; no
CNS metastases and no tumours abutting or invading major vessels. Primary
endpoint was PFS. Secondary endpoints included OS, response rates, duration
of response and safety.
Results: With longer follow-up, the previously reported significant pro-
longation of the primary endpoint PFS in pts receiving Bev  CG
Manegold et al. ASCO 2007 was maintained. The risk of progression or
death was reduced by 25% with Bev 7.5mg/kg, and 15% with Bev
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15mg/kg vs placebo (hazard ratio (HR) 0.75 (p0.003) and 0.85
(p0.046), respectively). Median OS was 13.1 months (mo) for CG alone,
13.6 mo for Bev 7.5mg/kg CG (HR vs placebo 0.92, 95% CI 0.77–1.10)
and 13.4 mo for Bev 15mg/kg  CG (HR 1.02, 95% CI 0.85–1.22).
Subsequent therapy following PD was received by the majority of pts.
This was not pre-specified in the protocol and thus introduced an
uncontrolled element to the OS analysis. No new safety signals were
identified.
Conclusions: Longer follow-up confirms the significant improvement
in PFS, the primary endpoint, with Bev combined with CG. The overall
survival benefit did not reach statistical significance; however, admin-
istration of heterogeneous subsequent therapy may have hampered the
detection of a significant difference. Together with E4599, BO17704
demonstrates that first-line Bev-based therapy provides important clin-
ical benefits for pts with advanced or recurrent non-squamous NSCLC.
Author Disclosures: M. Reck, Hoffmann-La Roche, Lilly, Bayer Health-
care, Merck; J. von Pawel, None; P. Zatlouka, None; R. Ramlau, None;
V. Gorbounova, None; V. Hirsh, Roche Ad Board(s); N. Leighl, Yes –
Roche, Lilly, Astra Zeneca, Amgen, Sanofi Aventis, Abraxis; Yes –
Roche, Astra Zeneca; Yes – Pfizer; J. Mezger, None; V. Archer, F.
Hoffmann-La Roche, Ltd; AstraZeneca PLC; F. Hoffmann-La Roche; C.
Manegold, F. Hoffmann-La Roche; F. Hoffmann-La Roche.
HIGHLIGHTED ABSTRACT SESSION
INTEGRATED PET/CT IN PRE-OPERATIVE STAGING
OF NON-SMALL CELL LUNG CANCER - RESULTS
FROM A RANDOMIZED CLINICAL TRIAL
B. M. Fischer1, U. Lassen1, J. Mortensen1, S. S. Larsen2, A. Loft1, A. K.
Bertelsen1, P. Clementsen3, A. Høgholm4, K. R. Larsen2, L. Højgaard1, et al.,
1Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen,
Denmark; 2Bispebjerg Hospital, 2200 Copenhagen, Denmark; 3Gentofte
Hospital, 2900 Hellerup, Denmark; 4Naestved Hospital, 4700 Naestved,
Denmark
Purpose/Objective(s): Fast and accurate staging is the cornerstone when
choosing therapy for patients with non-small cell lung cancer (NSCLC).
Integrated PET/CT was introduced as a promising tool in 2000; the
superior accuracy of PET/CT compared to both CT and PET alone has
been demonstrated. The purpose of the present prospective randomized
controlled study was to evaluate the clinical impact of PET/CT in staging
of NSCLC.
Materials/Methods: From January 2002 to February 2007 patients with
NSCLC referred for staging were randomized to conventional staging with
(PET/CTCS) or without PET/CT (CS). All patients were followed until
death or minimum 12 months. Primary endpoint was number of futile
thoracotomies. Futile thoracotomy was defined as benign lung lesion;
pathologically proven mediastinal lymph-node involvement (stage
IIIA-N2); stage IIIB-IV disease; explorative thoracotomy for any other
reason; recurrent disease or death from any cause within 1 year after
randomization.
Results: Eighty-six patients were randomized to the PET/CTCS arm and
91 to the CS arm. Mediastinoscopy was performed in 94% of the patients.
Fifty-five and 73 patients in PET/CTCS and CS group underwent
thoracotomy (p0.019). Of these respectively 16 and 38 patients had a
futile thoracotomy, resulting in an absolute and relative risk reduction in
number of futile thoracotomies of 23% and 44% (p0.011). The numbers
of justified thoracotomies were similar in the two groups.
Conclusions: PET/CT for initial staging of NSCLC reduces the number of
futile thoracotomies, as well as the total number of thoracotomies and it is
highly cost-effective.
Author Disclosures: B.M. Fischer, None; U. Lassen, None; J.
Mortensen, None; S.S. Larsen, None; A. Loft, None; A.K. Bertelsen,
None; P. Clementsen, None; A. Høgholm, None; K.R. Larsen, None; L.
Højgaard, None.
SIGNIFICANT REDUCTION OF BONE MARROW TOXIC-
ITY (BMT) FOR PATIENTS WITH LOCALLY ADVANCED
(LA) NSCLC TREATED WITH CONCURRENT CHEMO-
THERAPY (CT) AND PROTON BEAM THERAPY (PBT)
COMPARED TO INTENSITY MODULATED RADIATION
THERAPY (IMRT)
R. U. Komaki, S. V. Sejpal, X. Wei, P. K. Allen, R. Amos, R. Mohan,
J. Y. Chang, Z. Liao, L. Dong, J. D. Cox, M.D. Anderson Cancer Center,
Houston, TX
Background: Standard care for patients with locally advanced non-small-
cell lung cancer (LA NSCLC) is chemotherapy (CT) and Radiotherapy
(RT). These patients are at risk of bone marrow toxicity (BMT) which can
lead to delayed or missed treatments, hospitalizations, and/or the need
for growth factors. Because of its physical dose characteristics, Proton
beam therapy (PBT) can spare dose to critical structure such as bone
marrow compared to IMRT. We evaluated the incidence of BMT rate
in patients with LA NSCLC treated with concurrent CT/PBT vs. CT/
IMRT.
Methods: From 1/2003 to 6/2008, 142 patients with locally advanced
NSCLC were treated with CT and PBT (67 patients) or CT and IMRT (75
patients) with the following criteria: concurrent chemotherapy, no prior
thoracic RT, and dose of60 Gy or cobalt-60 Gy Equivalent (CGE) for
protons. Patients who had IMRT  3D-CRT or PBT were excluded.
Common Terminology Criteria (CTC) for adverse Events version 3.0 was
utilized to grade toxicities.
Results: Median follow up time for PBT and IMRT patients were 16.9
months (range, 3.1–25.7 months) and 9.8 months (range, 1.4 - 37.6
months), respectively. Median age was 62 (PBT) and 67 (IMRT)
(p0.07). KPS for both groups was 80. Nodal involvement was signifi-
cantly higher in IMRT group (83%) compared to the PBT group (42%)
(P0.001). Median dose in the PBT group was 74 (CGE) (range, 63–74
CGE) vs. 63 Gy (range, 60–76 Gy) in the IMRT group (p0.001). Patients
treated with CT and PBT experienced significantly less reduction in hemo-
globin (Hgb) (0.001), neutrophils (0.008), lymphocytes (0.001) and
white blood cells (WBC) (0.001) compared with those treated with CT/
IMRT. There was no significant difference in Platelets Count between two
groups. These differences remained when the GTV was considered.
Conclusions: Our preliminary analysis of BMT in patients with LA
NSCLC treated with CT/PBT shows a significant reduction in BMT for
Hbg, lymphocytes, neutrophils and WBC compared to those treated with
concurrent CT /IMRT. These findings suggest that concurrent CT/PBT,
when compared to those treated with concurrent CT /IMRT, may offer less
BMT and could allow for the use of more aggressive systemic regimens in
this group of patients. This needs to be tested prospectively in a random-
ized trial.
Author Disclosures: R.U. Komaki, None; S.V. Sejpal, None; X. Wei,
None; P.K. Allen, None; R. Amos, None; R. Mohan, None; J.Y. Chang,
None; Z. Liao, None; L. Dong, None; J.D. Cox, None.
PROTON THERAPY WITH CONCURRENT CHEMO-
THERAPY CAN REDUCE TOXICITY AND ALLOW
HIGHER RADIATION DOSES IN ADVANCED NON-
SMALL CELL LUNG CANCER
J. D. Cox, S. Sejpal, R. Komaki, J. Y. Chang, M. F. McAleer, Z. Liao, A.
Tsao, E. S. Kim, X. Wei, P. K. Allen, M.D. Anderson Cancer Center,
Houston, TX
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Introduction: Concurrent chemoradiation therapy is the standard of care
for locally advanced NSCLC but can cause life-threatening esophagitis
and pneumonitis. In addition, total tumor radiation doses often cannot be
increased without exceeding normal tissue tolerance. Treatment planning
studies for proton beam therapy (PBT) have shown that PBT may permit
higher total doses of radiation and considerably lessen the normal tissue
effects in these patients. However, these findings needed to be confirmed
clinically.
Methods: Sixty-seven consecutive patients were enrolled on one of two
IRB-approved phase II protocols permitting PBT and concurrent che-
motherapy. Patients who did not receive concurrent chemotherapy or
had had thoracic irradiation were excluded. Toxicities were graded
using Common Terminology Criteria for Adverse Events version 3.0.
Comparisons were made with data from similar patients treated with
3-dimensional conformal radiation therapy (3D CRT) (N84) and
intensity-modulated radiation therapy (IMRT) (N75).
Results: Median follow-up was: PBT patients, 11.4 months; IMRT
patients, 15.6 months; 3D CRT patients, 17.6 months. Median total
doses were: PBT, 74 cobalt Gy equivalent; IMRT, 63 Gy; 3D CRT, 63
Gy. Chemotherapy was platinum-based in 95% of patients. Esoph-
agitis occurred in 90.5% of 3D CRT patients and 93.3% of IMRT
patients and was grade 3 in 15.5% and 40.3%, respectively. In contrast,
esophagitis occurred in 77.6% of PBT patients and was grade 3 in only
5.9% (p  0.001). Importantly, grade 3 pneumonitis was seen in 33.3%
of 3D CRT patients and 9.3% of IMRT patients but in none of PBT
patients.
Conclusions: In this first report of phase II trials of PBT and concur-
rent chemotherapy for NSCLC, our results showed that higher doses of
radiation could be delivered to the tumor by PBT because of the
significantly reduced risk of esophagitis and pneumonitis. A random-
ized comparison of IMRT and PBT with concurrent chemotherapy is
planned.
Author Disclosures: J.D. Cox, None; S. Sejpal, None; R. Komaki, None;
J.Y. Chang, None; M.F. McAleer, None; Z. Liao, None; A. Tsao, None;
E.S. Kim, None; X. Wei, None; P.K. Allen, None.
NATIONAL CANCER INSTITUTE OF CANADA CLINICAL
TRIALS GROUP STUDY BR.24, A RANDOMIZED PLA-
CEBO CONTROLLED PHASE II TRIAL OF CEDIRANIB
(CED) PLUS CARBOPLATIN  PACLITAXEL (CP) IN
ADVANCED NON-SMALL CELL LUNG CANCER OF ANY
HISTOLOGY: FURTHER ANALYSES
S. A. Laurie, A. Arnold, F. A. Shepherd, M. Dediu, T. Ciuleanu, D.
Fenton, M. Zukin, G. Goss, K. Ding, L. Seymour, National Cancer
Institute of Canada Clinical Trials Group, Kingston, ON, Canada
Introduction: CED 45 and 30mg were tolerable and active with CP in
a phase I study. In BR.24, CED with CP increased response rate (RR),
and prolonged progression free survival (PFS) vs CP alone, warranting
further study. Concerns re: patient (pt) selection, adverse effects (AE) and
dose intensity (DI) led to an early amendment to reduce CED from 45 to
30mg and to exclude performance status (PS) 2 pts. Similar concerns at
phase II interim analysis precluded direct progression to phase III. Of note,
studies in colorectal cancer recently selected CED 20mg in combination
with mFOLFOX6 for phase III trials. Retrospective exploratory analyses
were performed to identify pts at risk of AEs.
Methods: Analyses explored baseline characteristics of all 296 random-
ized patients as predictors of safety outcomes. Dose response and DI were
examined in pts randomized to 45 or 30mg CED and by actual cycle dose
(45/30/20 mg).
Results: 30 vs 45mg CED: RR  PFS were similar, with improvements
seen in CED DI (37% were dose reduced), CP DI, hospitalizations,
SAEs (including grade (g) 5), rates of infection, diarrhea, dehydration,
mucositis, hand-foot syndrome and fatigue. CED cycles of 20 vs 30 vs
45mg showed toxicity-dose-relationship. For placebo or CED pts PS 2
predicted SAE, g5 AE and hospitalization (all cause). For CED pts, 45mg
dosing and PS 2 predicted severe GI toxicity; weight loss (WL)  5% 
hypoalbuminemia predicted for g5 AEs (all cause). Thrombosis/hemop-
tysis/cardiac failure/organ perforation were not inc. with CED; hyperten-
sion (38 vs 12%) and severe hemorrhage (5 vs 1%) were. Histologic
subtype did not predict toxicity or efficacy.
Conclusions: 30mg CED with CP inc. RR  PFS compared to CP
alone. A clear dose response for toxicity, but not efficacy, was demon-
strated. Poor PS pts do poorly with CP ( CED), while advanced
disease with significant WL/hypoalbuminemia inc. risk g5 AEs in CED
pts. NCIC CTG, in collaboration with ALTG, plans an international
randomized placebo controlled study of CED 20mg with CP, in NSCLC
(all histologies) pts with good PS, no significant WL or hypoalbuminemia.
Author Disclosures: S.A. Laurie, AstraZeneca; A. Arnold, None; F.A.
Shepherd, AstraZeneca; M. Dediu, None; T. Ciuleanu, None; D.
Fenton, None; M. Zukin, None; G. Goss, AstraZeneca; K. Ding, None;
L. Seymour, AstraZeneca.
K-RAS MUTATIONS (MT) AND EGFR-RELATED MARK-
ERS AS POTENTIAL PREDICTORS OF CETUXIMAB
BENEFIT IN 1ST LINE ADVANCED NSCLC: RESULTS
FROM THE BMS099 STUDY
S. Khambata-Ford1, C. T. Harbison1, L. L. Hart2, M. Awad1, L. Xu1, S.
Dakhil3, R. C. Hermann4, T. J. Lynch5, M. Weber6, 1Bristol Myers Squibb,
Princeton, NJ; 2Florida Cancer Specialists, Fort Myers, FL; 3Cancer
Center of Kansas, Wichita, KS; 4Northwest Georgia Oncology Center,
Marietta, GA; 5Massachussetts General Hospital Cancer Center, Boston,
MA; 6Bristol Myers Squibb, Wallingford, CT
Background: In the phase III BMS099 trial, cetuximab added to taxane/
carboplatin (TC) for 1st line treatment of advanced NSCLC resulted in
longer median overall survival (OS) and significantly better response rate
(RR) consistent with FLEX, but no difference in progression-free survival
(PFS). Our objective was to retrospectively evaluate K-Ras mt, EGFR mt,
EGFR gene copy number and EGFR protein expression as potential
patient-selection markers to optimize cetuximab therapeutic use.
Methods: Chemonaı¨ve patients (pts) with stage IIIB (wet)/IV NSCLC
(any histology or EGFR expression status) were randomized to TC 
cetuximab. K-Ras gene exon 2, and EGFR gene exons 18–21 were
sequenced bidirectionally using formalin-fixed paraffin embedded tissue
(FFPET)-derived genomic DNA. EGFR gene copy number was deter-
mined by fluorescence in situ hybridization (FISH) and EGFR expression
by immunohistochemistry (IHC). Analyses were blinded to clinical out-
come. The relationships between biomarker status and efficacy were
assessed with log-rank tests per treatment arm for treatment-specific
effects, and across the total evaluable population for prognostic effects.
Results: Samples were available for 225/676 randomized pts; 35/202
(17%) had K-Ras mt, 17/166 (10%) had EGFR sensitivity mt, 54/104
(52%) were EGFR FISH, and 131/148 (89%) were EGFR IHC.
Treatment-specific analyses revealed no significant associations between
biomarker status and PFS, OS or RR: neither statistically significant
differences between K-Ras wild type (wt) and mt pts in each treatment
arm, nor treatment specific effects by EGFR IHC status or EGFR mt
status. With all pts combined, OS was longer in the EGFR mt vs wt subset
(P0.09), and PFS was longer in EGFR IHC negative vs positive pts
(P0.048). Statistical analysis of EGFR FISH results is ongoing and will
be presented.
Conclusions: K-Ras mt status does not appear to be predictive for
cetuximab benefit in NSCLC, unlike in mCRC. No treatment-specific
effect on clinical activity was found with either EGFR IHC or EGFR mt
status. Further research is needed to identify predictive markers to select
patients most likely to benefit from cetuximab treatment.
Journal of Thoracic Oncology • Vol. 3, No. 11, Supplement 4, 2008
Copyright © 2008 by the International Association for the Study of Lung CancerS304
Author Disclosures: S. Khambata-Ford, Bristol-Myers Squibb; Bristol-
Myers Squibb, full time; C.T. Harbison, Agilent; Bristol-Myers Squibb,
full time; L.L. Hart, None; M. Awad, Bristol-Myers Squibb, full time; L.
Xu, Bristol-Myers Squibb, full time; S. Dakhil, None; R.C. Hermann,
None; T.J. Lynch, AstraZeneca; Genentech; ImClone Systems Incorpo-
rated; Bristol-Myers Squibb; Merck; Serono; GlaxoSmithKline; Mille-
nium; Roche; OSI; Genzyme; M. Weber, Bristol-Myers Squibb; Bristol-
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OVERALL SURVIVAL (OS) RESULTS FROM THE PHASE
III TRIAL BMS 099: CETUXIMABTAXANE/CARBOPLA-
TIN AS 1ST-LINE TREATMENT FOR ADVANCED NSCLC
T. J. Lynch1, T. Patel2, L. Dreisbach3, M. McCleod4, W. Heim5, R. C.
Hermann6, E. Paschold7, V. Pautret8, M. R. Weber9, L. L. Hart4, 1MGH
Cancer Center, Boston, MA; 2Mid Ohio Oncology Hematology, Colum-
bus, OH; 3Desert Hematology Oncology Medical Group, Rancho Mirage,
CA; 4Florida Cancer Specialists, Fort Myers, FL; 5Hematology & On-
cology Associates of Northeaster Pennsylvania, Dunmore, PA; 6Wellstar
Cancer Research Office, Marietta, GA; 7Piedmont Hematology Oncology
Associates, Winston-Salem, NC; 8Bristol Myers Squibb, Braine l’Alleud,
Belgium; 9Bristol Myers Squibb, Wallingford, CT
Background: Multiple phase II trials have shown that cetuximab is active
when added to 1st line platinum therapy in advanced NSCLC. The phase
III BMS099 trial compared taxane/carboplatincetuximab in this setting.
BMS099 was powered to evaluate a primary endpoint of progression-free
survival by independent review (PFS-IRRC), and intended to support the
pivotal FLEX trial (vinorelbine/cisplatincetuximab). In the initial report,
PFS-IRRC did not reach statistical significance (Lynch et al, 12th World
Conference on Lung Cancer; Seoul, Korea; 2007), but response rate
(RR-IRRC) and PFS by investigators were superior with cetuximab.
Methods: Chemonaı¨ve patients with wet stage IIIB or stage IV NSCLC,
without exclusion by histology or EGFR expression, were randomized to
taxane (docetaxel or paclitaxel, investigator’s choice on individual-patient
basis)/carboplatin with cetuximab or alone. PFS-IRRC was the primary
endpoint. RR and overall survival (OS) were secondary endpoints (OS
analysis: 75% power for a HR of 0.80). PFS and RR by investigators were
sensitivity analyses.
Results: A total of 676 patients were randomized. Median OS was
1.3-month greater with cetuximab (9.7 vs 8.4 mo); this difference did not
reach statistical significance (HR0.89, 95% CI:0.75–1.05; P0.17).
Outcomes were similar across several important subsets: histology (squa-
mous, HR0.87; adenocarcinoma, HR0.89), age (65y, HR0.92;
65, HR0.89) and taxane used (paclitaxel, HR0.89; docetaxel,
HR0.91). Final investigator assessments continued to show a statisti-
cally significant improvement in PFS with cetuximab (median, 4.4 vs 3.8
mo; HR 0.79, P0.0036), and increased RR (27.5% vs 22.5%). No
unexpected safety issues have emerged to date, updated safety analysis
will be presented.
Conclusions: Cetuximab increased OS, but the study lacked power to
reach statistical significance with a difference of this magnitude. RR and
PFS by investigators favored cetuximab. With a HR0.89 for OS, these
results are consistent with the statistically significant OS improvement
seen in FLEX (Pirker et al, ASCO 2008), and support the addition of
cetuximab to platinum doublets for the 1st line treatment of NSCLC.
Author Disclosures: T.J. Lynch, AZ, Genentech, Imclone, BMS, Merck,
Millenium, GSK, Sanofi, OSI, Chugai, BI; Genzyme; T. Patel, ImClone
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Dreisbach, None; M. McCleod, None; W. Heim, Stock Bristol-Myers
Squibb; R.C. Hermann, None; E. Paschold, None; V. Pautret, Bristol
Myers Squibb; M.R. Weber, Bristol Myers Squibb; Bristol Myers Squibb;
L.L. Hart, None.
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